PGNY
Progyny, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA Margin non-GAAP | 17.2% | first quarter of 2026 | — |
|
|
|||
| share repurchase program | 200M | recently completed call | — |
| Adjusted Earnings per Diluted Share non-GAAP | $1.89 | FY 2025 | — |
| Adjusted EBITDA non-GAAP | $222,092K | FY 2025 | — |
| Operating Cash Flow | $210.2M | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PGNY
this stock
Progyny, Inc.
|
$2.51B | +24.5% | +10.4% | 41.5 | 5.7% |
|
UNH
Unitedhealth Group Inc
|
$389.68B | +31.0% | +11.8% | 32.3 | 2.0% |
|
CVS
CVS HEALTH Corp
|
$135.48B | +34.5% | +10.9% | 46.6 | 1.6% |
|
ELV
Elevance Health, Inc.
|
$92.68B | +22.0% | +9.4% | 18.1 | 2.8% |
|
CI
Cigna Group
|
$80.55B | +11.2% | +11.2% | 12.9 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PGNY | +3.4% | +24.7% | +30.4% | +10.9% | +24.5% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | +3.7% | +23.1% | +22.1% | +10.6% | +14.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.